2019 American Transplant Congress
A National Survey of Immunosuppression Strategies in Intestinal Transplantation
*Purpose: Review the management of immunosuppression (IS) for intestinal transplantation (IT) in the USA*Methods: A survey was created and sent via email to surgical directors…2019 American Transplant Congress
Detection and Desensitization of Donor-Specific Antibody Reduces Risk of Early but Not Late Renal Transplant Failure in a Cohort of 1000 Cases
Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan
*Purpose: The Human Organ Transplant Act in Taiwan was promulgated in 1987 and, thereafter, organ transplantation from brain-dead donors legalized. To review the results of…2019 American Transplant Congress
Rituximab Desensitization to Liver Transplantaiton Recipients with Preformed Donor Specific Antibodies to Prevent Antibody Mediated Rejecton
Transplantation Surgery, Nagoya University Hospital, Nagoya City, Japan
*Purpose: Preformed donor-specific antibodies (DSA) are considered as a risk factor after solid organ transplantation. Strong DSA is associated with high mortality and increased risk…2019 American Transplant Congress
Low Frequency Of Canonical Human Leukocyte Antigen Alloimmunization In Heart Transplantation Candidates With Ventricular Assist Devices
*Purpose: Screening for anti-HLA antibodies in heart transplantation candidates is complicated by transfusions as well as by the presence of ventricular assist devices (VADs), which…2019 American Transplant Congress
Early CXCR5+PD1+ICOS+ Circulating Follicular T Helpers Are Associated with De Novo Donor-Specific Anti-HLA Antibodies after Renal Transplantation
*Purpose: Donor specific anti-HLA antibodies (DSA) are a major risk factor associated with renal allograft outcome. As a trigger of B cell antibody production, T…2019 American Transplant Congress
Outcomes in Preformed Donor-Specific Human Leukocyte Antibody Positive Living Kidney Transplant Recipients Desensitized with Intravenous Immunoglobulin and Rituximab
*Purpose: Donor-specific antibody (DSA) is associated with antibody-mediated rejection (ABMR) and is a significant immunologic barrier to graft and patient survival. Pre-transplant desensitization therapy has…2019 American Transplant Congress
High Prevalence of De Novo Donor-Specific Antibodies during Rejection after Liver Transplantation
Liver Transplant Unit, Hospital Clinic Barcelona, Barcelona, Spain
*Purpose: Anti-HLA donor specific antibodies (dnDSA) after liver transplantation (LT) are currently under investigation. Recent studies show an incidence of dnDSA after LT ranging from…2019 American Transplant Congress
De Novo Donor Specific Antibody and Panel Reactivity Antibody Are Critical Risk Factors for Antibody Mediated Rejection of Kidney Allograft after Simultaneous Liver-Kidney Transplantation (a Single Center Study Using Surveillance Renal Biopsies)
1Avalon Medical University, Willemstad, Netherlands Antilles, 2Cleveland Clinic, Cleveland, OH
*Purpose: Even though the liver may provide immunologic protection to the kidney from hyperacute rejection, previous publications suggest this protective effect is not sufficient to…2019 American Transplant Congress
ABO Incompatibility in Kidney Transplantation Can Increase a Safety Margin of Epitope Mismatch Levels against De Novo DSA Production
*Purpose: Chronic antibody-mediated rejection (cABMR) caused by de novo donor specific HLA antibodies (DSA) is one of major obstacles to long term graft outcome. ABO…2019 American Transplant Congress
Sequential Dosing of Rituximab and IVIg for Desensitization of Highly-HLA Sensitized (HS) Patients Awaiting HLAi Kidney Transplantation
Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Recent observations suggest that the use of IVIg + rituximab has a critical role in modifying allo-reactive B-cells prior to HLAi kidney transplantation, thus…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 47
- Next Page »